Application of chemosensitivity test in regional chemotherapy for hepatocellular carcinoma via hepatic artery and portal vein

Nie Lei; Wu DongDe; Zhang Feng; Xia XiaoQin

doi:10.3969/j.issn.1001-5256.2013.08.016

Issue 8

Aug. 2013

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2013 > 29(8): 616-619

PDF( 667 KB)

Application of chemosensitivity test in regional chemotherapy for hepatocellular carcinoma via hepatic artery and portal vein

DOI: 10.3969/j.issn.1001-5256.2013.08.016

Received Date: 2012-10-17
Published Date: 2013-08-20

Abstract

Abstract

Objective To evaluate the chemosensitivities of hepatocellular carcinoma (HCC) to different chemotherapy drugs by 3- (4, 5-dimethylthiazol-2-yl) -2, 5-diphenyl-2H tetrazolium bromide (MTT) assay and to provide guidance for individualized chemotherapy regimen in regional chemotherapy via the hepatic artery and portal vein.Methods Forty-two HCC samples were selected.Primary culture of HCC cells combined with MTT assay were used to evaluate the chemosensitivities of HCC to 5-fluorouracil (5-FU) , cisplatin (DDP) , mitomycin C (MMC) , adriamycin (ADM) , hydroxycamptothecine (HCPT) , gemcitabine (Gemzar) , and oxaliplatin (OXA) .Individualized chemotherapy regimens were developed according to the chemosensitivity test results to guide regional chemotherapy via the hepatic artery and portal vein in 24 of these patients (as an individualized chemotherapy group) .The therapeutic efficacy was compared with that of transcatheter arterial infusion performed in 20 patients (as a control group) .The chi-square test was used for comparison of sensitivity rate, and the rank-sum test was used for comparison of time to progression (TTP) .Results The sensitivity rates of HCC were 64.3% to OXA, 45.2% to HCPT, 40.5% to DDP, 38.1% to Gemzar, 33.3% to ADM, 21.4% to 5-FU, and 16.7% to MMC.Compared with the control group, the individualized chemotherapy group had a significantly higher objective response rate (50.0% vs 20.0%, P= 0.039) , a significantly higher disease control rate (70.8% vs 35.0%, P = 0.017) , and a significantly longer TTP ( (4.7±2.9) m vs (2.6±1.3) m, P = 0.032) .Conclusion In vitro chemosensitivity test based on MTT assay may be used to screen out the chemotherapy drugs in individualized chemotherapy for HCC and provide guidance for regional chemotherapy via the hepatic artery and portal vein, so as to improve the effect of chemotherapy.
- carcinoma,
- hepatocellular,
- drug screening assays

FullText(HTML)

References(10)

References

[1]YAN F.Clinical efficacy of double-intervention treatment of ad-vanced liver cancer[J].J Clin Exp Med, 2011, 10 (16) :1282-1283. (in Chinese) 严峰, 双介入治疗中晚期肝癌的临床效果观察[J].临床和实验医学杂志, 2011, 10 (16) :1282-1283.

[2]LI HP, TAO JS, GAO B, et al.The expression and clinical signifi-cance of resistance gene in hepatocellular carcinoma[J].J Clin Hepatol, 2011, 27 (9) :972-975. (in Chinese) 李海平, 陶建蜀, 高波, 等.肝细胞癌中耐药基因的表达及意义[J].临床肝胆病杂志, 2011, 27 (9) :972-975.

[3]UEDA H, FUKUCHI H, TANAKA C.Toxicity and efficacy of he-patic arterial infusion chemotherapy for advanced hepatocellular car-cinoma[J].Oncol Lett, 2012, 3 (2) :259-263.

[4]MAEJIMA K, TOKUNAGA A, KIYAMA T, et al.Chemosensitivity test for5-fluorouracil and5-chloro-2, 4-dihydroxypyridine pre-dicts outcome of gastric cancer patients receiving S-1postoperatively[J].Gastric Cancer, 2010, 13 (4) :231-237.

[5]WU B, ZHU JS, ZHANG Y, et al.Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer:One institu-tion's experience[J].World J Gastroenterol, 2008, 14 (19) :3064-3068.

[6]TANG DP, ZHANG CQ, TANG K, et al.Serial chemosensitivity test for liver cancer chemotherapy[J].Chin J Oncol Prev Treat, 2009, 1 (1) :18-20, 23. (in Chinese) 唐东平, 张翠卿, 唐凯, 等.系列化疗药敏或耐药试验在肝癌化疗中的应用研究[J].中国癌症防治杂志, 2009, 1 (1) :18-20, 23.

[7]SARGENT JM.The use of the MTT assay to study drug resistance in fresh tumour samples[J].Recent Results Cancer Res, 2003, 16 (1) :13-25.

[8]BURSTEIN HJ, MANGU PB, SOMERFIELD MR, et al.American So-ciety of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays[J].J Clin Oncol, 2011, 29 (24) :3328-3330.

[9]CHEN W, DENG J, YANG XJ, et al.The levels of TNF-α, sIL-2R and VEGF in patients with primary hepatic carcinoma after double intra-arterial infusion of anti-cancerous agents[J].J Clin Hepatol, 2010, 26 (2) :203-204, 209. (in Chinese) 陈卫, 邓俊, 杨小娟, 等.肝癌双灌注介入治疗后血清TNF-α、sIL-2R以及VEGF水平的变化与预后相关[J].临床肝胆病杂志, 2010, 26 (2) :203-204, 209.

[10]ZHENG JL, LIANG LJ, HU WJ, et al.Distribution of5-FU in rat plasma and liver tissue after local5-FU infusion[J].J South-ern Med Univ, 2008, 28 (5) :823-827. (in Chinese) 郑惊雷, 梁力建, 胡文杰, 等.区域性灌注化疗时5-FU的血液和肝脏组织药物浓度分布特征[J].南方医科大学学报, 2008, 28 (5) :823-827.

Relative Articles

[1]	Yu ZHANG, Yongfeng YANG. Thinking of the pathological diagnosis of unexplained liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(3): 498-503. doi: 10.3969/j.issn.1001-5256.2023.03.003
[2]	Xixuan WANG, Liangzi DING, Yang CHENG, Hao HAN, Jian YANG, Jiangqiang XIAO, Yi WANG, Ming ZHANG, Feng ZHANG, Yuzheng ZHUGE. Value of liver stiffness measured by acoustic radiation force impulse in diagnosis of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2022, 38(11): 2488-2492. doi: 10.3969/j.issn.1001-5256.2022.11.010
[3]	Jialing ZHOU, Bingqiong WANG, Yameng SUN, Tongtong MENG, Shanshan WU, Hong MA, Xiaojuan OU, Hong YOU, Jidong JIA, Xiaoning WU. Application value of liver stiffness measurement-to-platelet ratio index score in diagnosis of hepatitis B liver fibrosis and liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1529-1533. doi: 10.3969/j.issn.1001-5256.2022.07.014
[4]	Zhongjie YU, Wenxia ZHAO, Leixin FENG, Hanxiao WANG, Jianpeng LIU. Value of five noninvasive diagnostic methods for liver cirrhosis in diagnosis of traditional Chinese medicine syndrome types in patients with compensated hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(1): 104-109. doi: 10.3969/j.issn.1001-5256.2022.01.016
[5]	Yajie XU, Wenzheng YOU, Wanlei REN, Quanhe LONG, Xiangjun JIANG, Doudou HU. Application of pathological indicators based on liver biopsy in the diagnosis of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2021, 37(12): 2935-2938. doi: 10.3969/j.issn.1001-5256.2021.12.042
[6]	Yu WANG, Min WANG, Guanhua ZHANG, Fuliang HE, Xiaojuan OU, Jidong JIA. Clinical diagnosis, staging, and therapeutic principles of liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 17-21. doi: 10.3969/j.issn.1001-5256.2021.01.004
[7]	NIU XingJie, LIU ZhiHui, CUI FengMei, LIU YaoMin, WANG YanFei, ZHANG GuoMin, LIU JinXia. Value of peripheral blood long non-coding RNA-LET in the diagnosis of chronic hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2709-2713. doi: 10.3969/j.issn.1001-5256.2020.12.014
[8]	Zhou ShengYun, Duan ZhiHui. Noninvasive diagnosis of esophageal varices in liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(8): 1842-1846. doi: 10.3969/j.issn.1001-5256.2020.08.036
[9]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. Journal of Clinical Hepatology, 2019, 35(10): 2163-2172. doi: 10.3969/j.issn.1001-5256.2019.10.007
[10]	Li JiaNa, Zheng RuiQi, Li Na, Hu YuLin. The biological characteristics of GP73 and its value in the diagnosis of liver fibrosis and cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1361-1364. doi: 10.3969/j.issn.1001-5256.2019.06.040
[11]	Zhang YaNan, Jiang Chang, Xu Ying, Gao YanHang. Early diagnosis of spontaneous bacterial peritonitis in liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1851-1853. doi: 10.3969/j.issn.1001-5256.2019.08.045
[12]	Liu HaiFeng, Xu YongSheng, Zhang Yue, Zhao XiaoJu, Liu Zhao, Li JinKui, Yan RuiFeng, Xu Kai, Lei JunQiang. Value of magnetic resonance morphological imaging in the diagnosis and differentiation of post-hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(12): 2587-2591. doi: 10.3969/j.issn.1001-5256.2018.12.016
[13]	Yang ErNa, Cao WuKui. Research advances in noninvasive diagnosis of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2209-2213. doi: 10.3969/j.issn.1001-5256.2017.11.035
[14]	Du JingHua, Nan YueMin. Novel molecular diagnostic markers for liver fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 445-450. doi: 10.3969/j.issn.1001-5256.2017.03.009
[15]	Zhang Hui, Jia Lei, Lu: Dong, Xu YouQing. Value of serum cancer antigen12-5 level in diagnosis of peritoneal effusion in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2118-2120. doi: 10.3969/j.issn.1001-5256.2016.11.022
[16]	Deng Han, Qi XingShun, Zhu Qiang, Guo XiaoZhong. Alternative methods for diagnosis of esophageal varices in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1468-1473. doi: 10.3969/j.issn.1001-5256.2016.08.007
[17]	Zhao Wei. Clinical significance of plasma and urine neutrophil gelatinase-associated lipocalin levels in diagnosis of acute kindney injury in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1874-1877. doi: 10.3969/j.issn.1001-5256.2015.11.025
[18]	Wang Shuai, Hu DaRong. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites[J]. Journal of Clinical Hepatology, 2015, 31(7): 1018-1022. doi: 10.3969/j.issn.1001-5256.2015.07.005
[19]	Cai JunJun, Han Tao. Diagnosis and treatment of acute kidney injury in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1352-1356. doi: 10.3969/j.issn.1001-5256.2014.12.030
[20]	Jia KeDong, Shi ShuXian, Ruan YouBing. Detection of sialic acid in hepatitis involved liver cirrhosis and its significance for HCC diagnosis[J]. Journal of Clinical Hepatology, 2005, 21(2): 101-103.

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	阳丽华，梁英，刘仁峰，刘志昂. 甲状腺癌与甲状腺肿患者相关实验室指标的比较分析. 甘肃医药. 2025(01): 53-55+59 .
2.	张海苗. HBV感染原发性肝癌患者血常规指标的检测意义. 包头医学院学报. 2024(02): 67-71 .
3.	戴倩梅，丁体龙，代雪枫，于莉，陈策. 高敏丙型肝炎病毒核糖核酸在丙型肝炎中的诊断价值. 检验医学与临床. 2024(04): 487-490 .
4.	李晓宇，黄秀香，叶迎宾. 血清壳多糖酶3样蛋白1和PLT的比值与FIB-4指数在慢性乙型肝炎轻、中度诊断效价的比较. 标记免疫分析与临床. 2024(09): 1693-1697 .
5.	何萍，徐瑞，华秋菊，姜璐，王维平. 红细胞分布宽度与血小板比值对终末期肾病维持性血液透析患者动静脉内瘘失功的预测分析. 中国医师进修杂志. 2024(11): 988-994 .
6.	岳丽，孙佳瑶，刘龙芳. 脑小血管病患者外周血GPR30 mRNA、PLR、NPAS4表达及与认知功能、短期预后的关系. 临床误诊误治. 2023(01): 69-74 .
7.	杨杨，刘付弟，曾方林. 人类免疫缺陷病毒/乙型肝炎病毒合并感染者CD4~+T细胞计数和乙型肝炎病毒复制、中性粒细胞与淋巴细胞比值水平的相关性. 中国医药导报. 2023(10): 145-148 .
8.	王跃帮，常珊碧，王梦林，崔倩，裴兵. RLR在HBV相关性肝硬化诊断中的应用. 热带医学杂志. 2023(10): 1451-1455 .
9.	邱建华. PLT联合凝血功能检测对早期肝硬化的诊断价值分析. 现代诊断与治疗. 2023(22): 3433-3435 .
10.	赵霄君，谢建刚，段楚君，刘善收，王倩梅，思艺，王林潇，吴丹，王一帆，李俊杰. 血常规指标与脓毒症患者短期预后的相关性研究. 临床误诊误治. 2022(08): 73-77 .
11.	邵林楠，张树婷，王霓，周世航，刘铭. 血细胞各比值对慢性丙型肝炎病毒患者肝纤维化程度的评估. 临床血液学杂志. 2022(12): 874-877 .

Other cited types(7)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (393) PDF downloads(109)

Application of chemosensitivity test in regional chemotherapy for hepatocellular carcinoma via hepatic artery and portal vein

DOI: 10.3969/j.issn.1001-5256.2013.08.016